Press Releases July 29, 2026 07:30 AM

BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026

BrainsWay Announces Q2 2026 Financial Results Release and Conference Call Details

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
BWAY

BrainsWay Ltd., a leader in noninvasive brain stimulation technologies, announced it will release its second quarter 2026 financial results on August 12, 2026, followed by a conference call and webcast to discuss operational highlights and business updates.

BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
BWAY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BrainsWay will report Q2 2026 financial results before U.S. market open on August 12, 2026.
  • The company will hold an English conference call and webcast at 8:30 AM ET with a Hebrew call the following day.
  • BrainsWay specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) with FDA-cleared treatments for major depressive disorder, OCD, and smoking addiction.

BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that it will report its second quarter 2026 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, August 12, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

US Conference Call Dial-In & Webcast Information

In English:

Date:Wednesday, August 12, 2026Time:8:30 AM Eastern TimeUnited States:1-877-269-7751International:1-201-389-0908Conference ID:13761391Webcast:Link


In Hebrew:

Date:Thursday, August 13, 2026Time:11:00 AM Israeli Daylight TimeWebcast:Link


The conference calls will be broadcast live and the English webcast will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Contacts:
BrainsWay:
Ido Marom
Chief Financial Officer
[email protected]

Investors:
Jeff Warren
LifeSci Advisors
[email protected]


Risks

  • Financial performance risks related to quarterly results which could impact investor sentiment.
  • Clinical trial outcomes for ongoing studies in psychiatric and neurological disorders may affect future growth.
  • Market competition and regulatory developments in medical device and mental health technology sectors.

More from Press Releases

Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sep 11, 2026 EverCommerce Announces an Increase and Extension of its Share Repurchase Program Sep 11, 2026 Grupo Aeroportuario del Pacifico Announces the Execution of Bank Credit Facilities Totaling Ps. 8,000 Million Sep 11, 2026 Eastern International Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 11, 2026 ArrowMark Financial Corp. Announces Q2 Results and Special Distribution of $0.10 and Monthly Cash Distribution of $0.15 per Share for September 2026 Sep 11, 2026